Publications by authors named "Andrea Asmussen"
Background: There are conflicting data on a potential association between obesity and atopic dermatitis (AD). The purpose of this study was to investigate the relationship between obesity and AD disease severity.
Methods: Patients from the TREATgermany registry cohort were divided into three groups according to their body mass index (BMI).
Article Synopsis
- Eczema herpeticum (EH) is a skin infection from the herpes virus that affects patients with atopic dermatitis (AD), and a study sought to evaluate its prevalence and characteristics in a larger group of patients.* -
- In a study of 893 AD patients, 21.8% experienced at least one episode of EH, with over half of those (54.9%) suffering from multiple episodes.* -
- The findings indicate a high recurrence of EH among AD patients, yet no distinct clinical traits were found to differentiate these patients, apart from an increased number of allergies.*
Background: TREATgermany is a multicenter registry including patients with moderate-to-severe atopic dermatitis (AD) from currently 74 study centers (university clinics, hospitals and practices) in Germany. As of August 31, 2021, 1,230 adult patients were enrolled.
Methods: In TREATgermany, patients and physicians fill in questionnaires pertaining to symptoms, disease severity, quality of life, depressiveness, and fatigue.
TREATgermany is an investigator-initiated prospective disease registry. It investigates physician- and patient-reported disease severity (Eczema Area and Severity Index (EASI), objective Scoring Atopic Dermatitis (oSCORAD), Investigator Global Assessment, Patient-Oriented Eczema Measure (POEM), Patient Global Assessment (PGA)), patient-reported symptoms (itch, sleep loss, depressive symptoms), therapy courses and dermatological quality of life (DLQI) in moderate-to-severe atopic dermatitis with SCORAD > 20. 1,134 atopic dermatitis patients (mean age 41.
View Article and Find Full Text PDFThis interim analysis from the atopic dermatitis registry TREATgermany shows robust long-term efficacy, favourable safety and high persistence of dupilumab under real life conditions.
View Article and Find Full Text PDF